7th Annual Molecular Diagnostics Europe
Date: May 6 - 9, 2019
Venue: Lisbon Marriott Hotel, Lisbon, Portugal
Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean

About Molecular Diagnostics Europe


Cambridge Healthtech Institute’s Seventh International Molecular Diagnostics Europe event will move to a larger venue for 2019 - the Lisbon Marriott Hotel - from 6-9 May. This meeting provides a nexus for diagnostic developers in academia and industry as well as end-users in the pharmaceutical and healthcare sector to gain a comprehensive picture of molecular diagnostics in prenatal, oncology, infectious disease, point-of-care, liquid biopsy, plus new coverage of biomarkers for immunotherapy, and companion diagnostics for immuno-oncology. This exciting area has attracted attendance of over 400 delegates to learn what novel technologies, platforms and applications are emerging that will impact future healthcare delivery and pharmaceutical research. Join us next spring at this expanding event at the epicenter of diagnostics. While most speakers will be invited, if you would like to be considered for a podium presentation, please contact us.

2018 Keynote Presentations


Extending the Scope of Prenatal Diagnosis for Monogenic Disorders: Non-Invasive Prenatal Diagnosis
Lyn Chitty, PhD, MBBS, MRCOG, Great Ormond Street Hospital for Children NHS Foundation Trust

An Overview on the Emergence of Arbovirus Epidemics in the World and Their Consequences
Pedro Fernando da Costa Vasconcelos, MD, PhD, Ministry of Health

The Evidence Base for Circulating Tumour DNA Blood-Based Biomarkers for the Early Detection of Cancer: A Systematic Mapping Review
Jacqui Shaw, PhD, University of Leicester

Multi-Step Real-Time PCR Coupled with HRM Enables Rapid Mutation Assessment Prior to Targeted Re-Sequencing
G. Mike Makrigiorgos, PhD, Dana Farber and Harvard Medical School

Upcoming New Diagnostic Regulations and How They Will Impact Developers of AMR POC Tests
Doris-Ann Williams, MBE, British In Vitro Diagnostics Association (BIVDA)

Phenogenomic Subtyping of CTCs to Identify Biomarkers that Improve Prostate Cancer Patient Outcomes
Howard I. Scher, MD, Memorial Sloan Kettering Cancer Center